MAP Pharmaceuticals News

MAP Pharmaceuticals received a Complete Response Letter from the FDA on March 26th, 2012.

"We believe that LEVADEX has the potential to be an important treatment for many of the 30 million Americans who suffer from migraine, and we will continue to closely collaborate with the FDA to address the issues raised in the Complete Response letter as quickly as possible." was caused primarily by a decrease in expenses related to the LEVADEX ... (more)

The company said it anticipates operating expenses for the remainder of 2012, excluding non-cash charges such as stock-based compensation and depreciation, to be approximately $35M-$37M. Not included in its outlook are potential incremental launch costs which will be determined once the company has clarity around the Complete Response letter for ... (more)

The company said, "Following receipt of the Complete Response letter from the FDA on March 26 for our LEVADEX NDA submission, we will meet with the FDA in the second quarter of this year and we look forward to gaining clarity around the issues raised in the letter.

A live webcast of each event will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com . A replay also will be available within 24 hours for seven days following each presentation.